Akademik Veri Yönetim Sistemi
Turkish Journal of Gastroenterology, cilt.9, sa.4, ss.354-357, 1998 (SCI-Expanded)
Helicobacter pylori (H.pylori) infection has a very high prevalence in our country and therefore presents an important health problem. Nowadays, the most preferable treatments in the eradication of H.pylori are the and short term triple treatments. The indispensable drugs in this treatment regimen are proton pomp inhibitors. In this prospective study we investigated the potential benefits of lansoprazole in H.pylori eradication as compared to omeprazole. Fiftytwo patients with documented duodenal ulcers gastritis and H.pylori positivity were included in the study. Patients of the same age and gender were randomly allocated to two groups. Twenty six of 52 patients received a triple treatment for one week consisting of omeprazole 20 mg bid, clarithromycin 500 mg bid and metro-nidazole 500 mg bid. The other 26 patients received a triple treatment for one week consisting of lansoprazole 30 mg bid, clarithromycin 500 mg bid and metronidazole 500 mg bid. Four weeks after the completion of treatment, endoscopic examination was performed to detect the presence of H. pylori infection. Eradication was accepted as negativity of both the CLO test and histological absence of H. pylori. The eradication rate was found to be 92.3% (24/26) and 88.4% (23/26) in the omeprazole and lansoprazole groups respectively. The difference between the two groups was not significant. In conclusion, a high success rate was obtained in the eradication of H. pylori with one week-triple treatment including a proton pump inhibitor, clarithromycin and metronidazole. However there was no significant difference in eradication rates between the two proton pomp inhibitors.